Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Research & Development (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Research & Development data on record, last reported at $34.0 million in Q4 2025.

  • For Q4 2025, Research & Development rose 1.65% year-over-year to $34.0 million; the TTM value through Dec 2025 reached $142.3 million, up 13.54%, while the annual FY2025 figure was $142.3 million, 13.54% up from the prior year.
  • Research & Development reached $34.0 million in Q4 2025 per TRDA's latest filing, down from $38.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $38.4 million in Q3 2025 and bottomed at $15.7 million in Q4 2022.
  • Average Research & Development over 4 years is $27.1 million, with a median of $28.4 million recorded in 2023.
  • Peak YoY movement for Research & Development: soared 80.37% in 2023, then rose 1.65% in 2025.
  • A 4-year view of Research & Development shows it stood at $15.7 million in 2022, then skyrocketed by 80.37% to $28.3 million in 2023, then grew by 18.08% to $33.4 million in 2024, then rose by 1.65% to $34.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $34.0 million in Q4 2025, $38.4 million in Q3 2025, and $37.9 million in Q2 2025.